US 9,809,610 B2
Compounds and compositions as kinase inhibitors
Matthew T. Burger, Belmont, MA (US); Savithri Ramurthy, Emeryville, CA (US); and Benjamin R. Taft, Oakland, CA (US)
Assigned to Novartis AG, Basel (CH)
Filed by Matthew T. Burger, Belmont, MA (US); Savithri Ramurthy, Emeryville, CA (US); and Benjamin R. Taft, Oakland, CA (US)
Filed on Jan. 4, 2017, as Appl. No. 15/397,787.
Application 15/397,787 is a continuation of application No. 14/851,249, filed on Sep. 11, 2015, granted, now 9,573,969.
Claims priority of provisional application 62/049,469, filed on Sep. 12, 2014.
Prior Publication US 2017/0114083 A1, Apr. 27, 2017
Int. Cl. C07D 403/12 (2006.01); C07D 213/74 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); A61K 31/675 (2006.01); C07F 9/6558 (2006.01)
CPC C07F 9/65583 (2013.01) [A61K 31/675 (2013.01); C07D 213/74 (2013.01); C07D 403/12 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01)] 6 Claims
 
1. A method of treating a proliferative disorder selected from ovarian cancer, non-small cell lung cancer and cancers driven by Ras mutations, comprising administering to a subject having said proliferative disorder a therapeutically effective amount of a compound of formula (I)

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt thereof;
wherein
R1 is selected from hydrogen and methyl;
R2 is selected from pyridinyl and phenyl; wherein phenyl or pyridinyl can be substituted with a group selected from trifluoromethyl, 1,1-difluoroethyl and 2-fluoropropan-2-yl;
X and Y are independently selected from N and C—OCH2CHR3R4; wherein R3 is selected from hydrogen and OH; and R4 is phosphonooxy; with the proviso that if X is N, Y is C—OCH2CHR3R4 and if Y is N, X is C—OCH2CHR3R4; and
Z is selected from N and CH.